Want to see AU:M7T full AI Analyst Report?
Top Page
Mach7 Technologies
(Sydney:M7T)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.26
â–¼(-8.57% Downside)
Action:Reiterated
Date:09/16/26
The score is held down primarily by weak financial performance (losses, revenue decline, and negative full-year operating/free cash flow) and bearish technicals (price below key moving averages and negative MACD). Positives—low debt and cash on hand, plus earnings-call signs of cost discipline, high gross margin, and improved second-half momentum—provide some support but are not yet sufficient to outweigh the profitability and trend risks.
Positive Factors
Recurring Revenue Base
A predominantly recurring revenue model can improve visibility and customer retention compared with one-time license sales. The sizable recurring base gives Mach7 a foundation for compounding contract value as it expands modules, deployments, and enterprise adoption.
Negative Factors
Revenue and Profitability Decline
A substantial revenue contraction alongside a large net loss indicates that the business has not yet established a durable path to profitable growth. Continued weakness could limit reinvestment capacity and make future operating leverage dependent on successful execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Revenue Base
A predominantly recurring revenue model can improve visibility and customer retention compared with one-time license sales. The sizable recurring base gives Mach7 a foundation for compounding contract value as it expands modules, deployments, and enterprise adoption.
Read all positive factors
Mach7 Technologies (M7T) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$61.10M
Dividend YieldN/A
Average Volume (3M)63.59K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-17.35%
EPS Growth-47.29%
CountryAU
Employees167
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding235,009,720
10 Day Avg. Volume68,635
30 Day Avg. Volume63,592
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.97
Price to Sales (P/S)2.44
P/FCF Ratio-51.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.40Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$29.66M
Mach7 Technologies Business Overview & Revenue Model
Company Description
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterpris...
How the Company Makes Money
Mach7 Technologies primarily makes money by selling enterprise imaging software to healthcare providers (e.g., hospitals, health systems, and imaging networks). Revenue is generally generated through (1) software licensing or subscription fees for...
Mach7 Technologies Earnings Call Summary
Earnings Call Date:Aug 27, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Mar 03, 2027
Earnings Call Sentiment Positive
The call presented a cautious but constructive tone: FY'26 was framed as a deliberate reset that materially improved the business foundation—higher-quality recurring revenue mix, a 93% gross margin, reduced operating costs, a stronger leadership team, and clear second-half commercial momentum (ARR run rate +7.6% constant currency; H2 revenue +15% vs H1). However, meaningful near-term challenges remain including a 17% reported revenue decline, several sizable customer losses (notably VHA and Trinity Health), an $8.9M net loss, and FX-driven reporting headwinds. Management emphasized stabilization and a roadmap (Flamingo modules, Epic integrations, focused partnerships) to prove growth in FY'27. Overall, positives around margin, cash/no debt, cost discipline and H2 recovery modestly outweigh the lowlights, supporting cautious optimism.Positive Updates
Predominantly Recurring Revenue Base
Total revenue of $27.9M for FY'26 with $23.4M of recurring revenue; contracted ARR (CAR) $25.5M and ARR run rate $23.5M, reflecting a more subscription-driven, predictable revenue mix.
Negative Updates
Year-on-Year Revenue Decline
Total revenue declined 17% versus prior year (as reported), driven primarily by lower capital license revenue and softer professional services.
Read all updates
Q4-2026 Updates
Positive
Negative
Predominantly Recurring Revenue Base
Total revenue of $27.9M for FY'26 with $23.4M of recurring revenue; contracted ARR (CAR) $25.5M and ARR run rate $23.5M, reflecting a more subscription-driven, predictable revenue mix.
Read all positive updates
Company Guidance
Management set four clear FY‑27 priorities—ARR growth, new customer wins, Flamingo adoption and OpEx discipline—and gave FY‑26 baselines to measure progress: FY‑26 total revenue $27.9M (recurring $23.4M), CAR $25.5M and an ARR run‑rate of $23.5M; revenue was down 17% YoY (recurring down 8%), capital license revenue $1.5M (‑17%), while ARR run‑rate was up 7.6% on a constant‑currency basis and CAR was down 9% constant currency. They closed FY‑26 with operating expenses $26.7M (down $5.1M or 16%), gross margin 93%, adjusted EBITDA loss of $0.9M, net loss before amortization $2.9M, net loss after tax $8.9M, cash $19.9M and no debt; cash receipts were $28M and operating cash flow was negative for the year but positive in 3 of 4 quarters (Q1 ‑$3.7M, Q2 ~breakeven, Q3 +$1.2M, Q4 +$1.1M). Second‑half momentum (constant‑currency revenue H2 $15.6M vs H1 $13.5M, +15%), stronger bookings (TCV up 80% H2 vs H1; 86% ARR‑type; 40% of orders in Q4; 21% new logos) and one‑offs (restructuring $1.9M, deferred tax write‑off ≈$1M) provide the starting point for proving recurring revenue growth, module adoption and operating leverage in FY‑27.Mach7 Technologies Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
40
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 27.91M | 33.79M | 17.24M | 30.06M | 27.08M |
| Gross Profit | -1.89M | 8.38M | -6.42M | 9.35M | -2.57M |
| EBITDA | -1.18M | -733.63K | -15.09M | 2.09M | 2.80M |
| Net Income | -8.93M | -6.20M | -7.97M | -1.05M | -4.17M |
Balance Sheet | |||||
| Total Assets | 50.50M | 64.21M | 73.03M | 82.31M | 78.92M |
| Cash, Cash Equivalents and Short-Term Investments | 19.92M | 23.07M | 26.18M | 23.39M | 25.75M |
| Total Debt | 80.39K | 1.12M | 1.27M | 1.20M | 1.33M |
| Total Liabilities | 15.93M | 18.63M | 21.17M | 22.82M | 20.55M |
| Stockholders Equity | 34.56M | 45.58M | 51.86M | 59.48M | 58.38M |
Cash Flow | |||||
| Free Cash Flow | -1.33M | 112.92K | 3.30M | -2.97M | 5.94M |
| Operating Cash Flow | -1.26M | 868.59K | 3.45M | -2.61M | 6.37M |
| Investing Cash Flow | -915.97K | -1.70M | -391.31K | -361.01K | -438.56K |
| Financing Cash Flow | -164.03K | -2.43M | -32.08K | -68.63K | 547.61K |
Mach7 Technologies Technical Analysis
Positive
0.28
Price Trends
0.25
Positive
0.27
Negative
0.30
Negative
Market Momentum
<0.01
Negative
65.83
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:M7T, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.25, and below the 200-day MA of 0.30, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.83 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:M7T.
Mach7 Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$20.73B | 78.41 | 63.19% | 0.35% | 22.87% | 130.30% | |
65 Neutral | AU$148.48M | 64.71 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$109.10M | -6.93 | -203.69% | ― | -1.53% | 28.29% | |
47 Neutral | AU$61.10M | -6.84 | -24.29% | ― | -17.35% | -47.29% | |
45 Neutral | AU$22.74M | -1.22 | -58.13% | ― | 2.08% | -195.31% | |
44 Neutral | AU$425.45M | -15.23 | -30.04% | ― | <0.01% | 2.08% |
* Healthcare Sector Average
AU:M7T
Mach7 Technologies
0.27
-0.02
-7.02%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.14
-0.05
-26.32%
AU:PME
Pro Medicus Limited
196.00
-72.00
-26.86%
AU:BMT
Beamtree Holdings Ltd
0.08
-0.12
-61.50%
AU:AYA
Artrya Limited
2.65
-0.64
-19.45%
AU:ALC
Alcidion Group Limited
0.12
0.02
15.00%
Mach7 Technologies Corporate Events
Mach7 Builds Cash Momentum as Modular Imaging Strategy Advances
Oct 25, 2026
Mach7 Technologies reported its fourth consecutive quarter of positive operating cash flow in Q1 FY27, achieving its first ever positive Q1 operating cash flow of A$0.3 million and ending the period with A$19.3 million in cash and no debt. Annual ...
Mach7 Technologies Sets Fully Virtual AGM for November 2026
Oct 23, 2026
Mach7 Technologies Limited has called its Annual General Meeting for 24 November 2026 at 10.00 a.m. AEDT, to be conducted entirely via Zoom as a virtual webinar, reflecting its continued use of digital platforms for shareholder engagement. The com...
Mach7 issues 750,000 unquoted options under employee incentive scheme
Oct 20, 2026
Mach7 Technologies Limited has issued 750,000 unquoted options under its employee incentive scheme, with these securities not being listed on the ASX while subject to transfer restrictions. The move indicates continued use of equity-based remunera...
Mach7 Technologies Sets Q1 FY27 Results Release and Investor Webinar
Oct 14, 2026
Mach7 Technologies has announced it will release its Q1 FY27 results for the quarter ended 30 September 2026 on 26 October 2026, underscoring ongoing transparency with the market around its financial performance. Following the release, CEO Teri Th...
Mach7 Technologies Confirms Shawni Hadfield as CFO to Drive Next Growth Phase
Oct 2, 2026
Mach7 Technologies has appointed interim Chief Financial Officer Shawni Hadfield as permanent CFO, effective immediately, formalizing a leadership change aimed at supporting the company’s next phase of sustainable growth. Hadfield, who joine...
Mach7 Technologies Reports Lapse of 466,667 Performance Rights
Oct 1, 2026
Mach7 Technologies has reported the cessation of 466,667 performance rights, classified as M7TAB securities on the ASX. The rights lapsed on 30 September 2026 because the conditions attached to them were not met or became incapable of being satisf...
Mach7 Technologies Sets Key Dates for 2026 AGM and Board Nominations
Sep 29, 2026
Mach7 Technologies has scheduled its 2026 Annual General Meeting for 10:00 a.m. Melbourne time on Tuesday, 24 November 2026, with further details to be set out in a formal Notice of Meeting. The company has also set 6 October 2026 as the closing d...
Mach7 Technologies Options Lapse and Expire, Clarifying Capital Structure
Sep 1, 2026
Mach7 Technologies has updated the market on changes to its issued capital following the cessation of certain option securities. The company reported that a tranche of 16,666 options lapsed after their conditions could not be satisfied, while a fu...
Mach7 Technologies Outlines Parameters and Limits of FY26 Results Briefing
Aug 27, 2026
Mach7 Technologies has released its FY26 results presentation, outlining general background information on its activities and financial disclosures as of 28 August 2026. The document emphasizes that the material is informational only, not a prospe...
Mach7 Technologies Files 2026 Preliminary Final Report
Aug 27, 2026
Mach7 Technologies has released its Appendix 4E preliminary final report and audited financial statements for the year ended 30 June 2026. The disclosure, made in line with ASX listing rules, signals completion of the company’s annual report...
Mach7 Technologies Announces Lapse of Conditional Options
Aug 24, 2026
Mach7 Technologies Limited has notified the market of changes to its issued capital following the cessation of certain options on its register. The announcement details the lapse of conditional rights to securities, reflecting adjustments in the c...
Mach7 Options Lapse Reduces Potential Share Dilution
Aug 17, 2026
Mach7 Technologies has updated the market on changes to its capital structure, notifying the cessation of several tranches of options listed under the ASX code M7TAJ. The options, which carried various exercise prices and expiry dates, have lapsed...
Mach7 Technologies sets date for FY26 results and investor webinar
Aug 11, 2026
Mach7 Technologies will release its financial results for the year ended 30 June 2026 on 28 August, underscoring a key reporting milestone for the ASX-listed healthcare software group. The company is positioning its enterprise imaging platform as ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.